Amarillo Biosciences Agrees to Clinical Trials in China of low-dose oral interfe

[Guest guest]

Amarillo Biosciences Agrees to Clinical Trials in China

Amarillo Globe-News (Texas) (KRT) - Nov. 28, 2006

Nov. 28--Amarillo Biosciences has entered into a licensing and supply

agreement with CytoPharm, a Taiwan-based biopharmaceutical company, to

conduct clinical trials of low-dose oral interferon and to seek regulatory

approval for it as a treatment for influenza and hepatitis B.

The clinical trials are expected to begin next year.

Interferon is a naturally occuring protein produced by the body that

" interferes " with viruses. The oral medication, in addition to treating the

flu and hepatitis B, is being tested to treat oral warts sufffered by HIV

patients and Behcet's, an autoimmune disease.

Terms of the deal were not released, but the agreement calls for CytoPharm

to make payments to Amarillo Biosciences as it reaches certain clinical

milestones. CytoPharm also will pay royalties on low-dose oral interferon

sales in Taiwan and China.

Amarillo Biosciences chief executive ph Cummins said the deal, which

took 62 weeks to complete, shows investors who might have been leery about

the technology that a major company is willing to support the emerging

treatment -- in no less than one of the largest markets in the world

But the real benefit, Cummins said, will be the clinical data. The

information researchers are able to glean from the trials CytoPharm will

perform can be used in efforts to persuade other countries to approve

interferon.

The Chinese and Taiwanese clinical trials will take place independent of

Amarillo Biosciences' Phase II trials before the U.S. Food and Drug

Administration.

Claus , a consultant to Amarillo Biosciences, said the company was

interested in taking interferon to Thailand, Brunei, Myanmar, the

Philippines, Malaysia, Singapore and Indonesia.

Amarillo Biosciences has invested nearly $38 million in its 22-year history

to demonstrate oral interferon's therpuetic uses.

" With the fast growing economies and vastly improving health care systems in

both China and Taiwan, patients' demands for newer and better drugs have

become much stronger, " said Ellson Chen, CytoPharm's chairman. " (Hepatitis

is a major disease in the region, and governments spend billions of

dollars to deal with this deadly disease. "

Shares of the company gained 27 percent, or 17 cents, to 80 cents, on more

than 15 times the shares' normal daily trading volume.

CytoPharm is a closely held company focusing on the development of

biopharmaceuticals for virus-infected diseases and cancers. It was founded

in 2002 by Ho Tung Chemical, Vita Genomics, and banks and venture capital

firms.

http://www.therapeuticsdaily.com/news/article.cfm?contentvalue=1164414 & contentty\

pe=sentryarticle & channelID=31

_________________________________________________________________

Get free, personalized commercial-free online radio with MSN Radio powered

by Pandora http://radio.msn.com/?icid=T002MSN03A07001

[Guest guest]

Amarillo Biosciences Agrees to Clinical Trials in China

Amarillo Globe-News (Texas) (KRT) - Nov. 28, 2006

Nov. 28--Amarillo Biosciences has entered into a licensing and supply

agreement with CytoPharm, a Taiwan-based biopharmaceutical company, to

conduct clinical trials of low-dose oral interferon and to seek regulatory

approval for it as a treatment for influenza and hepatitis B.

The clinical trials are expected to begin next year.

Interferon is a naturally occuring protein produced by the body that

" interferes " with viruses. The oral medication, in addition to treating the

flu and hepatitis B, is being tested to treat oral warts sufffered by HIV

patients and Behcet's, an autoimmune disease.

Terms of the deal were not released, but the agreement calls for CytoPharm

to make payments to Amarillo Biosciences as it reaches certain clinical

milestones. CytoPharm also will pay royalties on low-dose oral interferon

sales in Taiwan and China.

Amarillo Biosciences chief executive ph Cummins said the deal, which

took 62 weeks to complete, shows investors who might have been leery about

the technology that a major company is willing to support the emerging

treatment -- in no less than one of the largest markets in the world

But the real benefit, Cummins said, will be the clinical data. The

information researchers are able to glean from the trials CytoPharm will

perform can be used in efforts to persuade other countries to approve

interferon.

The Chinese and Taiwanese clinical trials will take place independent of

Amarillo Biosciences' Phase II trials before the U.S. Food and Drug

Administration.

Claus , a consultant to Amarillo Biosciences, said the company was

interested in taking interferon to Thailand, Brunei, Myanmar, the

Philippines, Malaysia, Singapore and Indonesia.

Amarillo Biosciences has invested nearly $38 million in its 22-year history

to demonstrate oral interferon's therpuetic uses.

" With the fast growing economies and vastly improving health care systems in

both China and Taiwan, patients' demands for newer and better drugs have

become much stronger, " said Ellson Chen, CytoPharm's chairman. " (Hepatitis

is a major disease in the region, and governments spend billions of

dollars to deal with this deadly disease. "

Shares of the company gained 27 percent, or 17 cents, to 80 cents, on more

than 15 times the shares' normal daily trading volume.

CytoPharm is a closely held company focusing on the development of

biopharmaceuticals for virus-infected diseases and cancers. It was founded

in 2002 by Ho Tung Chemical, Vita Genomics, and banks and venture capital

firms.

http://www.therapeuticsdaily.com/news/article.cfm?contentvalue=1164414 & contentty\

pe=sentryarticle & channelID=31

_________________________________________________________________

Get free, personalized commercial-free online radio with MSN Radio powered

by Pandora http://radio.msn.com/?icid=T002MSN03A07001